TrialCancer research and treatment2016

A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets.

Rachna Arora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.